A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

DLBCL Clinical Trial

Official title:

A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03205046
• Other study ID #: ACE-LY-110
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: June 29, 2017
• Est. completion date: November 20, 2019

Study information

• Verified date: December 2020
• Source: Acerta Pharma BV
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the safety of acalabrutinib and vistusertib when taken in combination.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 25
• Est. completion date: November 20, 2019
• Est. primary completion date: November 20, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 130 Years

Eligibility

Inclusion Criteria:

1. Diagnosis of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) as documented by medical records and with histology based on criteria established by The World Health Organization (WHO):

• If a subject has de novo DLBCL, the diagnosis is confirmed by biopsy and is immunohistologically characterized as de novo germinal center B-cell-like (GCB) DLBCL or de novo non-GCB DLBCL.

• If the subjects has Richter's Syndrome (RS), the diagnosis is confirmed by biopsy and is immunohistologically characterized as transformation to DLBCL.

• If the subjects has transformed DLBCL, the diagnosis is confirmed by biopsy and is immunohistologically characterized as transformation to DLBCL from indolent lymphoma (eg, follicular lymphoma).

2. Men and women =18 years of age.

3. Prior treatment for lymphoid malignancy:

• If the subject has DLBCL, there is no curative option with conventional therapy and the prior treatment included = 1 prior combination chemoimmunotherapy regimen.

• If the subject has RS, the subject must have had =1 prior treatment with a combination chemoimmunotherapy regimen.

4. Eastern Cooperative Oncology Group (ECOG) performance status of =2.

5. Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of a =1.5 cm lesion, as measured in the longest dimension by computed tomography [CT] scan).

Exclusion Criteria:

1. As judged by the Investigator, any evidence of severe or uncontrolled systemic disease (eg, severe hepatic impairment, interstitial lung disease [bilateral, diffuse, parenchymal lung disease]), or current unstable or uncompensated respiratory or cardiac conditions, or uncontrolled hypertension, history of, or active, bleeding diatheses (eg, hemophilia or von Willebrand disease) or uncontrolled active systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment), or intravenous anti-infective treatment within 2 weeks before first dose of study drug.

2. Diagnosis of PMBCL.

3. Current refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal (GI) function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.

4. History of central nervous system (CNS) lymphoma, leptomeningeal disease or spinal cord compression.

5. Any clinically significant pre-existing severe renal disease (eg, glomerulonephritis, nephritic syndrome, Fanconi Syndrome or renal tubular acidosis) or high risk of developing severe renal impairment.

6. Abnormal echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) at baseline (left ventricular ejection fraction [LVEF] <40% and shortening fraction <15%). Appropriate correction to be used, if a MUGA is performed.

7. Mean resting corrected QT interval (QTc) calculated using Fridericia's formula (QTcF) >450 msec obtained from 3 electrocardiograms (ECGs); family or personal history of long or short QT syndrome; Brugada syndrome or known history of QTc prolongation or torsade de pointes within 12 months of the subject entering the study.

Related Conditions & MeSH terms

• DLBCL
• Richter Syndrome

Intervention

Drug:
• acalabrutinib
Acalabrutinib is a selective, irreversible small molecule Bruton's tyrosine kinase (BTK) inhibitor.
• vistusertib
Vistusertib is an inhibitor of mechanistic target of rapamycin (mTOR) kinase

Locations

Country	Name	City	State
United Kingdom	Research Site	Headington
United Kingdom	Research Site	London
United Kingdom	Research Site	Nottingham
United Kingdom	Research Site	Sutton
United States	Research Site	Bethesda	Maryland
United States	Research Site	Fairway	Kansas
United States	Research Site	Hackensack	New Jersey
United States	Research Site	Nashville	Tennessee
United States	Research Site	Omaha	Nebraska
United States	Research Site	Rochester	Minnesota
United States	Research Site	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Acerta Pharma BV

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Treatment-Emergent Adverse Events (AEs)	Safety assessments comprised type, frequency, severity, and relationship to either or both study drug of any AEs or abnormalities of laboratory tests; serious adverse events (SAEs); dose-limiting toxicities (DLTs); or AEs that led to dose modification, dose delay, or discontinuation of study drug(s).	From first dose of study drug until 30 days post last dose

External Links

•   Related Info
•   Related Info